Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Naomi N
NN
Hunder
Herschel
H
Wallen
Jianhong
J
Cao
Deborah W
DW
Hendricks
John Z
JZ
Reilly
Rebecca
R
Rodmyre
Achim
A
Jungbluth
Sacha
S
Gnjatic
John A
JA
Thompson
Cassian
C
Yee
D000912:Antibodies, Neoplasm / Q000097:blood; D000951:Antigens, Neoplasm / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D007074:Immunoglobulin G; D008565:Membrane Proteins